Notice of Intent (NOI) to Issue a Request for Applications (RFA) entitled “Fiscal Year 17 Biomass Research and Development Initiative (BRDI)
Funding Opportunity ID: 291245 Opportunity Number: DE-FOA-0001711 Opportunity Title: Notice of Intent (NOI) to Issue a Request for Applications (RFA) entitled “Fiscal Year 17 Biomass Research and Development Initiative (BRDI)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: OtherCategory of Funding Activity: EnergyCategory Explanation: CFDA Number(s): 81.087Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Additional Information on Eligibility: Agency Code: DOE-GFOAgency Name: Department of EnergyGolden Field OfficePosted Date: Jan 13, 2017Close Date: NOI - No applicationsLast Updated Date: Jan 13, 2017Award Ceiling: $2Award Floor: $1Estimated Total Program Funding: $0Expected Number of Awards: 0Description: The U.S. Department of Agriculture (USDA), National Institute of Food and Agriculture (NIFA) in conjunction with the U.S. Department of Energy (DOE), Office of Energy Efficiency and Renewable Energy (EERE), Bioenergy Technologies Office (BETO) intends to issue a Request for Applications (RFA) entitled “Fiscal Year 17 Biomass Research and Development Initiative (BRDI).” For fiscal year (FY) 2017, the BRDI program requires that funded projects address at least one (1) of the following three (3) legislatively mandated technical (topic) areas: 1) Feedstocks development – T...
Publication date: Available online 16 November 2019Source: Journal of Health EconomicsAuthor(s): Dimitris Christelis, Dimitris Georgarakos, Anna Sanz-de-GaldeanoAbstractEconomic theory predicts that a reduction in background risk should induce financial risk-taking, particularly for individuals with low stock market participation costs. Hence, health insurance coverage could affect financial risk-taking by offsetting health-related background risk. We use a regression discontinuity design to examine whether Medicare eligibility at age 65 increases stockholding in the US and find that it does so for those with college educa...
In this study, serum IL6 was measured by ELISA, and the HSD11B1rs12086634(T/G) polymorphism was analyzed using a TaqMan allelic discrimination assay technique. There were statistically significant differences between the two studied groups concerning the serum IL-6 level and HSD11B1rs12086634(T/G) genotype distribution, with increased serum IL6 and increased frequencies of the GG and TG genotypes in patients with PCO. The GG genotype of HSD11B1 rs12086634(T/G) and its associated high level of serum IL-6 may represent genetic risk factors for PCOS.
Publication date: Available online 17 November 2019Source: European UrologyAuthor(s): Tom Marcelissen, Kevin Rademakers
Publication date: Available online 17 November 2019Source: European UrologyAuthor(s): Zhengzheng Xu, Guangzhe Ge, Bao Guan, Zhentao Lei, Xueyu Hao, Yuanyuan Zhou, Yue Shi, Huan Lu, Jilu Wang, Ding Peng, XiKang Wu, Huiying He, Bao Zhang, Xuesong Li, Liqun Zhou, Weimin Ci
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Pirus Ghadjar, Thomas Wiegel
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Elise De Bleser, Piet Ost
ConclusionThe CFQL-2 is a brief, reliable scale that effectively measures psychosocial aspects of QoL and is sensitive to changes in QoL in families of children with ASD or related neurodevelopmental disorders. Child externalizing behavior is strongly associated with reductions in multiple aspects of child and family psychosocial QoL.
ConclusionThis meta-analysis suggested a significant association between MTHFR gene polymorphism (C677T and A1298C) and ASD risk.
ConclusionGiven that obtaining negative margins is important in reducing the risk of recurrence, the method of surgical resection utilized is based on the amount of future functional residual hepatic parenchyma.
ConclusionsTattooing of axillary LNs is safe and easily performed. Tattooing was helpful in identifying the marked LN in the majority of cases. This technique helps to ensure that metastatic LNs are identified and removed at surgery after NAT.